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Aims
In the central nervous system, NMDA receptors play a
pivotal role, however, their role in pancreatic islets has
been largely unexplored or is controversial. We hypothe-
sized that NMDA receptors are involved in glucose stimu-
lated insulin secretion from beta cells and might serve as
novel drug targets for diabetes treatment.
Methods
We generated mice with a pancreas-specific deletion of all
NMDA receptors. The phenotype of these mice and their
pancreatic islets were characterized in terms of insulin
secretion, glucose tolerance and calcium oscillations. We
also pharmacologically inhibited the NMDA receptors in
vitro and in vivo. Subsequently, insulin secretion from iso-
lated mouse and human islets as well as blood glucose and
plasma insulin concentrations were analyzed in mice and
via a clinical trial in type 2 diabetic patients.
Results
Functional NMDA receptors are expressed in insulin
producing cells. A pancreas specific NMDA receptor
knockout selectively increases glucose stimulated insulin
secretion in vitro and improves glucose tolerance in vivo.
The pharmacological inhibition of NMDA receptors
selectively increases glucose stimulated insulin secretion
in vitro and improves glucose tolerance in C57Bl/6 and
diabetic mice. In addition, we performed a clinical trial in
patients with type 2 diabetes and provided evidence that
the NMDA receptor antagonist Dextromethorphan
(DXM) lowers blood glucose levels and increases insulin
secretion without the risk of hypoglycemia.
Conclusion
We show for the first time that NMDA receptors can be
targeted genetically and pharmacologically in mice and
men to selectively increase glucose stimulated insulin
secretion with improvement of glucose tolerance. We
uncovered a new role for NMDA receptors in the pancreas
and showed that inhibiting these receptors might serve as a
useful treatment of human diabetes in pediatric and adult
patients.
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